BioWorld

May 2, 2007

Series A And B Rounds Up As Early Stage Model Evolves

Of the $2.1 billion in venture capital invested in global biotechnology companies last quarter, the majority went into earlier-stage financings, according to data from BioWorld Financial Watch and BioWorld Snapshots. (BioWorld Today) Read More

House Hearing Probes Range Of Ways To Improve The FDA

Optimer's CDAD Drug Starts Second Pivotal Phase III Trial

NewCo News: Start-Up Solace Raises $15M In Series A For Pain Drugs

Italian Firm Eurand Files For IPO On Nasdaq Of Up To $153M

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for April 20, 2026.

Man holding raised arm with illustrated overlay of nerves

Biohaven reports details on discovery of BHV-2100

BioWorld Science

Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...

Elderly woman holding illustration of brain with missing puzzle piece

Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’

BioWorld

The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...

New GABA(B) receptor PAMs revealed in Addex Pharma patents

BioWorld Science

Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...

Novel caspase-2 inhibitor shows in vivo neuroprotective effects

BioWorld Science

Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...